AstraZeneca vaccine shows robust immune response in Bangladesh: study

Staff Correspondent | Published: 00:25, May 17,2021

 
 

Oxford-AstraZeneca Covid vaccine Covishield has induced robust immune response in Bangladeshi adults after one and two months of vaccination with the first dose, according to a study.

The Institute of Epidemiology, Disease Control and Research, the International Centre for Diarrhoeal Disease Research, Bangladesh and the United States Agency for International Development conducted the joint study. The study findings were disclosed on May 13 in a release.

The study found that 92 per cent of the people who received the first dose had high immune response after one month of vaccination and 97 per cent of the vaccinated people had even higher immune response two months after the first dose of vaccination.

It found that there was no significant difference in the presence of antibodies among the jab takers with or without comorbidity.

Among the 120 participants of the study, 46 were infected with Covid-19 earlier.

The participants with previous infection history showed more robust response after receiving the first dose of the vaccine.

ICDDR,B senior scientist Firdausi Qadri, who is leading the study, said, ‘We now know that the Covishield vaccine induces robust immune response in Bangladeshi adults. We will continue working on evaluating the neutralising ability of the antibody.’

IEDCR director Professor Tahmina Shirin said that their analysis confirmed that the vaccine worked and people should get it when their turn came. The vaccination programme across Bangladesh started on February 7 by administering the Oxford-AstraZeneca vaccine manufactured by the Serum Institute of India under the brand name of Covishield,

Bangladesh has so far obtained 1.02 crore doses of the vaccine manufactured by Serum.

The vaccination programme has faced a challenge lately as the Serum in March stopped supplying the vaccine in breach of the contract, under which the Bangladesh government paid it in advance to get 3 crore doses by June.

Serum has supplied 70 lakh doses and Indian government sent 32 lakh doses as gift.

The government has stopped the first dose inoculation since April 26 and it has 7 lakh doses which are being used for the second dose inoculation.

Among those who have received the first dose, over 14 lakh will not get the second dose in due time due to the vaccine shortage.

More about:

Want stories like this in your inbox?

Sign up to exclusive daily email

Advertisement

 

Advertisement

images